New cases come from SEER 12. Deaths come from U.S. Mortality. All Races, Both Sexes. Rates are Age-Adjusted. Modeled trend lines were calculated from the underlying rates using the Joinpoint Trend Analysis Software. The 2020 incidence rate is displayed but not used in the fit of the trend line(s). Impact of COVID on SEER Cancer Incidence 2020 data
New cases are also referred to as incident cases in other publications. Rates of new cases are also referred to as incidence rates.
Age-Adjusted Rates of New Cases/Deaths Per 100,000 & 5-Year Relative Survival Percentages
Year
Rate of New Cases — SEER 8
Rate of New Cases — SEER 12
Death Rate — U.S.
5-Year Relative Survival — SEER 8
Observed
Modeled Trend
Observed
Modeled Trend
Observed
Modeled Trend
Observed
Modeled Trend
1975
19.07
19.60
-
-
5.50
5.53
72.22%
72.71%
1976
19.61
19.65
-
-
5.59
5.53
73.01%
73.33%
1977
18.82
19.70
-
-
5.52
5.53
74.27%
73.94%
1978
19.79
19.76
-
-
5.44
5.41
75.90%
74.54%
1979
19.74
19.81
-
-
5.25
5.30
74.11%
75.13%
1980
19.95
19.87
-
-
5.17
5.19
75.01%
75.70%
1981
20.10
19.92
-
-
5.07
5.08
78.58%
76.27%
1982
19.83
19.97
-
-
4.99
4.97
76.37%
76.82%
1983
19.50
20.03
-
-
4.88
4.86
77.50%
77.36%
1984
20.39
20.08
-
-
4.74
4.76
77.68%
77.89%
1985
20.08
20.14
-
-
4.67
4.66
77.34%
78.41%
1986
20.95
20.19
-
-
4.53
4.56
77.93%
78.92%
1987
21.16
20.25
-
-
4.41
4.46
78.59%
79.42%
1988
20.36
20.30
-
-
4.41
4.46
79.40%
79.91%
1989
20.72
20.36
-
-
4.48
4.45
80.86%
80.39%
1990
20.66
20.41
-
-
4.49
4.44
81.17%
80.36%
1991
20.56
20.47
-
-
4.42
4.43
80.39%
80.33%
1992
20.78
20.53
20.33
19.98
4.46
4.43
80.06%
80.31%
1993
20.85
20.58
20.32
20.00
4.47
4.42
80.33%
80.28%
1994
20.07
20.64
19.61
20.01
4.47
4.41
80.75%
80.25%
1995
20.09
20.70
19.70
20.03
4.35
4.41
81.76%
80.22%
1996
20.41
20.75
19.79
20.04
4.41
4.40
79.90%
80.19%
1997
20.71
20.81
20.10
20.06
4.39
4.39
79.01%
80.16%
1998
20.97
20.87
20.04
20.08
4.38
4.39
79.13%
80.13%
1999
21.26
20.92
20.17
20.09
4.36
4.38
77.75%
80.10%
2000
21.01
20.98
20.01
20.11
4.32
4.37
80.53%
80.07%
2001
21.27
21.04
20.27
20.13
4.35
4.38
81.56%
80.05%
2002
20.70
21.09
19.81
20.14
4.43
4.38
80.36%
80.02%
2003
21.23
21.15
20.57
20.16
4.30
4.38
80.89%
79.99%
2004
21.30
21.21
20.70
20.18
4.42
4.39
80.67%
79.96%
2005
21.16
21.27
20.13
20.19
4.42
4.39
80.25%
79.93%
2006
20.87
21.33
19.89
20.21
4.41
4.39
81.11%
79.90%
2007
21.26
21.12
20.31
20.23
4.44
4.40
79.14%
79.87%
2008
20.98
20.92
19.80
19.96
4.41
4.40
78.02%
79.84%
2009
20.45
20.71
19.37
19.71
4.37
4.41
79.09%
79.81%
2010
20.84
20.51
19.86
19.45
4.44
4.41
78.20%
79.78%
2011
20.07
20.32
19.02
19.20
4.44
4.41
79.29%
79.75%
2012
20.25
20.12
19.05
18.95
4.40
4.42
78.34%
79.72%
2013
19.69
19.93
18.51
18.71
4.46
4.42
79.37%
79.69%
2014
20.00
19.73
18.51
18.46
4.38
4.42
79.77%
79.66%
2015
19.83
19.54
18.41
18.22
4.41
4.43
81.54%
79.63%
2016
19.41
19.36
18.26
17.99
4.43
4.43
80.06%
79.60%
2017
19.18
19.17
17.77
17.76
4.33
4.34
-
79.57%
2018
18.66
18.98
17.12
17.53
4.23
4.24
-
79.54%
2019
18.64
18.80
17.27
17.30
4.17
4.15
-
79.51%
2020
17.26
18.62
16.10
17.08
4.06
4.06
-
79.48%
2021
18.58
18.44
16.95
16.85
4.05
4.07
-
79.45%
2022
-
-
-
-
4.08
4.07
-
79.43%
Rate of New Cases and Deaths per 100,000: The rate of new cases of bladder cancer was 18.2 per 100,000 men and women per year. The death rate was 4.1 per 100,000 men and women per year. These rates are age-adjusted and based on 2017–2021 cases and 2018–2022 deaths.
Lifetime Risk of Developing Cancer: Approximately 2.2 percent of men and women will be diagnosed with bladder cancer at some point during their lifetime, based on 2018–2021 data, excluding 2020 due to COVID.
Prevalence of This Cancer: In 2021, there were an estimated 730,044 people living with bladder cancer in the United States.
Did You Know? Video Series
Did You Know? Video Series
How Many People Survive 5 Years Or More after Being Diagnosed with Bladder Cancer?
Relative survival is an estimate of the percentage of patients who would be expected to survive the effects of their cancer. It excludes the risk of dying from other causes. Because survival statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment can vary greatly.
5-Year Relative Survival
78.4%
Based on data from SEER 22 (Excluding IL/MA) 2014–2020. Gray figures represent those who have died from bladder cancer. Green figures represent those who have survived 5 years or more.
Cancer stage at diagnosis, which refers to extent of a cancer in the body, determines treatment options and has a strong influence on the length of survival. In general, if the cancer is found only in the part of the body where it started it is localized (sometimes referred to as stage 1). If it has spread to a different part of the body, the stage is regional or distant. The earlier bladder cancer is caught, the better chance a person has of surviving five years after being diagnosed. For bladder cancer, 33.9% are diagnosed at the local stage. The 5-year relative survival for localized bladder cancer is 71.7%.
Percent of Cases & 5-Year Relative Survival by Stage at Diagnosis: Bladder Cancer
Stage
Percent of Cases
5-Year Relative Survival
In Situ Only in Originating Layer of Cells
50%
97.2%
Localized Confined to Primary Site
34%
71.7%
Regional Spread to Regional Lymph Nodes
7%
39.5%
Distant Cancer Has Metastasized
5%
8.8%
Unknown Unstaged
4%
52.7%
Percent of Cases by Stage
In Situ (50%) Only in Originating Layer of Cells
Localized (34%) Confined to Primary Site
Regional (7%) Spread to Regional Lymph Nodes
Distant (5%) Cancer Has Metastasized
Unknown (4%) Unstaged
5-Year Relative Survival
SEER 22 (Excluding IL/MA) 2014–2020, All Races, Both Sexes by SEER Combined Summary Stage
Compared to other cancers, bladder cancer is fairly common.
Rank
Common Types of Cancer
Estimated New Cases 2024
Estimated Deaths 2024
1.
Breast Cancer (Female)
310,720
42,250
2.
Prostate Cancer
299,010
35,250
3.
Lung and Bronchus Cancer
234,580
125,070
4.
Colorectal Cancer
152,810
53,010
5.
Melanoma of the Skin
100,640
8,290
6.
Bladder Cancer
83,190
16,840
7.
Kidney and Renal Pelvis Cancer
81,610
14,390
8.
Non-Hodgkin Lymphoma
80,620
20,140
9.
Uterine Cancer
67,880
13,250
10.
Pancreatic Cancer
66,440
51,750
Bladder cancer represents 4.2% of all new cancer cases in the U.S.
4.2%
In 2024, it is estimated that there will be 83,190 new cases of bladder cancer and an estimated 16,840 people will die of this disease.
Who Gets This Cancer?
Bladder cancer becomes more common with age and is more common in men than women. The rate of new cases of bladder cancer was 18.2 per 100,000 men and women per year based on 2017–2021 cases, age-adjusted.
Rate of New Cases per 100,000 Persons by Race/Ethnicity & Sex: Bladder Cancer
Males
All Races
31.6
Hispanic
17.0
Non-Hispanic American Indian/Alaska Native
20.0
Non-Hispanic Asian/Pacific Islander
14.7
Non-Hispanic Black
18.9
Non-Hispanic White
37.7
Females
All Races
7.8
Hispanic
4.7
Non-Hispanic American Indian/Alaska Native
5.1
Non-Hispanic Asian/Pacific Islander
3.5
Non-Hispanic Black
5.8
Non-Hispanic White
9.3
All Races
7.8
17.0
Hispanic
4.7
20.0
Non-Hispanic American Indian/ Alaska Native
5.1
14.7
Non-Hispanic Asian / Pacific Islander
3.5
18.9
Non-Hispanic Black
5.8
37.7
Non-Hispanic White
9.3
SEER 22 2017–2021, Age-Adjusted
Percent of New Cases by Age Group: Bladder Cancer
Age Range
Percent of New Cases
<20
0.1%
20–34
0.4%
35–44
1.2%
45–54
4.8%
55–64
17.4%
65–74
32.2%
75–84
29.6%
>84
14.3%
<2020–3435–4445–5455–6465–7475–84>84Age0510152025303540Percent of New Cases0400.1%0.4%1.2%4.8%17.4%32.2%29.6%14.3%
Bladder cancer is most frequently diagnosed among people aged 65–74.
Median Age At Diagnosis
73
SEER 22 2017–2021, All Races, Both Sexes
Who Dies From This Cancer?
Bladder cancer is the tenth leading cause of cancer death in the United States. The death rate was 4.1 per 100,000 men and women per year based on 2018–2022 deaths, age-adjusted.
Death Rate per 100,000 Persons by Race/Ethnicity & Sex: Bladder Cancer
Males
All Races
7.1
Hispanic
3.8
Non-Hispanic American Indian/Alaska Native
3.7
Non-Hispanic Asian/Pacific Islander
2.8
Non-Hispanic Black
5.3
Non-Hispanic White
8.0
Females
All Races
2.0
Hispanic
1.2
Non-Hispanic American Indian/Alaska Native
1.9
Non-Hispanic Asian/Pacific Islander
0.9
Non-Hispanic Black
2.1
Non-Hispanic White
2.2
7.1
All Races
2.0
3.8
Hispanic
1.2
3.7
Non-Hispanic American Indian/ Alaska Native
1.9
2.8
Non-Hispanic Asian / Pacific Islander
0.9
5.3
Non-Hispanic Black
2.1
8.0
Non-Hispanic White
2.2
U.S. 2018–2022, Age-Adjusted
Percent of Deaths by Age Group: Bladder Cancer
Age Range
Percent of Deaths
<20
0.0%
20–34
0.1%
35–44
0.4%
45–54
2.2%
55–64
10.3%
65–74
22.7%
75–84
32.4%
>84
31.9%
<2020–3435–4445–5455–6465–7475–84>84Age0510152025303540Percent of Deaths0400.1%0.4%2.2%10.3%22.7%32.4%31.9%
The percent of bladder cancer deaths is highest among people aged 75–84.
Median Age At Death
79
U.S. 2018–2022, All Races, Both Sexes
Changes Over Time
Keeping track of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments.
Using statistical models for analysis, age-adjusted rates for new bladder cancer cases have been falling on average 1.0% each year over 2012–2021. Age-adjusted death rates have been falling on average 0.9% each year over 2013–2022. 5-year relative survival trends are shown below.
New Cases, Deaths and 5-Year Relative Survival
19801985199019952000200520102015Year197520220510152025Rate Per 100,000 Persons025
Rate of New Cases
Death Rate
New cases come from SEER 8. Deaths come from U.S. Mortality. All Races, Both Sexes. Rates are Age-Adjusted. Modeled trend lines were calculated from the underlying rates using the Joinpoint Trend Analysis Software. The 2020 incidence rate is displayed but not used in the fit of the trend line(s). Impact of COVID on SEER Cancer Incidence 2020 data
SEER 8 5-Year Relative Survival Percent from 1975–2016, All Races, Both Sexes. Modeled trend lines were calculated from the underlying rates using the Joinpoint Survival Model Software.
With SEER*Explorer, you can...
Create custom graphs and tables
Download data and images
Share links to results
SEER*Explorer is an interactive website that provides easy access to a wide range of SEER cancer statistics. It provides detailed statistics for a cancer site by sex, race, calendar year, age, and for a selected number of cancer sites, by stage and histology.
Figure: Anatomy of the male urinary system (left)
and female urinary system (right)
Figure: Anatomy of the male urinary system (left) and female urinary system (right) showing the kidneys, ureters, bladder, and urethra.
Figure: Anatomy of the male urinary system (left)
and female urinary system (right)
Figure: Anatomy of the male urinary system (left) and female urinary system (right) showing the kidneys, ureters, bladder, and urethra.
The bladder is a hollow organ in the lower part of the abdomen. It is shaped like a small balloon and has a muscular wall that allows it to get larger or smaller. The urine passes from the two kidneys into the bladder through two tubes called ureters. The bladder is emptied through another tube called the urethra.
Cancer that is confined to the lining of the bladder is called superficial bladder cancer. Cancer that begins in the transitional cells may spread through the lining of the bladder and invade the muscle wall of the bladder or spread to nearby organs and lymph nodes; this is called invasive bladder cancer.
All statistics in this report are based on statistics from SEER and the Centers for Disease Control and Prevention's National Center for Health Statistics. Most can be found within SEER*Explorer.
Suggested Citation
All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.
These stat facts focus on population statistics that are based on the U.S. population. Because these statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. To see tailored statistics, browse SEER*Explorer. To see statistics for a specific state, go to the State Cancer Profiles.
The statistics presented in these stat facts are based on the most recent data available, most of which can be found in SEER*Explorer. In some cases, different year spans may be used.
Estimates of new cases and deaths for 2024 are projections made by the American Cancer Society (ACS), based on earlier reported data.
Cancer is a complex topic. There is a wide range of information available. These stat facts do not address causes, symptoms, diagnosis, treatment, follow-up care, or decision making, although links are provided to information in many of these areas.